Nasacort and Nasonex are both allergy nasal sprays that contain drugs called corticosteroids. With allergies, the body’s immune system responds to an allergen, or trigger. This causes symptoms such as ...

Although the court ruled that the patent is valid, it also said that Apotex’s product would not infringe on the patent. Merck had filed a patent infringement suit against Apotex in December 2009. The ...

Schering-Plough's successful allergy medication gets an updated ad campaign. The Nasonex Bee is buzzing a new tune. Schering-Plough is working with BBDO to update its successful Nasonex (mometasone ...

With spring allergies in the air, two prescription-products-gone-over-the-counter recently – Astepro and Nasonex -- have sprung creative campaigns. Surrounded by flowers, and clothed and posed as if ...

Mometasone (as furoate monohydrate) 50mcg/spray; contains benzalkonium chloride. Not for treating asthma. Avoid use in patients with recent nasal ulcers, surgery, or injury that has not healed.

The FDA’s Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase ...

IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces ...

A once-daily dose of Schering-Plough’s allergy drug, Nasonex (mometasone), is safe and effective for the treatment of nasal polyps and nasal congestion related to the condition, according to new ...

Apotex announced the launch of Mometasone Furoate Monohydrate Nasal Spray, the generic version of Merck's Nasonex. Nasonex is indicated for the treatment of nasal congestion. It is a corticosteroid ...

The FDA's new proposed guidelines on drug advertising read like a full-employment act for medical copywriters and graphic designers: they control font size, white space, context, contrast, placement, ...

With sales just shy of $1.3 billion in 2011, Nasonex allergy spray is Merck's fifth-best-selling drug. The rebuff comes at a tough time for the drugmaker, however. In August, it loses loses patent ...

Please provide your email address to receive an email when new articles are posted on . Perrigo announced that the FDA has approved mometasone furoate monohydrate, an intranasal corticosteroid nasal ...